Breast Cancer Clinical Trial

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Summary

The purpose of this study is to find out how often the researchers can avoid an ALND in patients with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have only 1 or 2 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients aged ≥18 years with biopsy-proven invasive breast cancer
Patients with cTx, cT1, or cT2 tumors with palpable ipsilateral mobile adenopathy of level I/II axillary nodes with biopsy-proven (either by pre-operative biopsy or intraoperative frozen section) nodal metastasis (cN1) who are undergoing upfront surgery

Patients with tumors of the HR+/HER2- subtype, defined as:

HR+: Positive for estrogen receptor and/or progesterone receptor staining, indicated by ≥1% immunoreactive tumor nuclei
HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay

Exclusion Criteria:

Patients with prior ipsilateral breast cancer
Patients who are pregnant
Patients with stage IV disease at presentation
Patients with advanced regional disease (cN2/cN3)

Study is for people with:

Breast Cancer

Estimated Enrollment:

78

Study ID:

NCT04854005

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Hartford Healthcare Cancer Alliance (Data collection only)
Hartford Connecticut, 06102, United States More Info
Niamey Wilson, MD
Contact
203-694-5200
University of Michigan (Data Collection Only)
Ann Arbor Michigan, 48109, United States More Info
Melissa Pilewskie, MD
Contact
734-647-8902
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge New Jersey, 07920, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown New Jersey, 07748, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Memorial Sloan Kettering Bergen (Consent Only)
Montvale New Jersey, 07645, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Memorial Sloan Kettering Suffolk - Commack (Consent Only)
Commack New York, 11725, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Memorial Sloan Kettering Westchester (Consent Only)
Harrison New York, 10604, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Anita Mamtani, MD
Principal Investigator
Memorial Sloan Kettering Nassau (Consent Only)
Uniondale New York, 11553, United States More Info
Anita Mamtani, MD
Contact
646-888-6864
Lehigh Valley Health Network (Dara Collection Only)
Allentown Pennsylvania, 18103, United States More Info
Heiwon Chung, MD
Contact
610-402-7884

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

78

Study ID:

NCT04854005

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.